India's largest biotech firm Biocon could be developing potential "blockbuster" drugs for the treatment of cancer and diabetes, but the company's chairman-cum-managing director Kiran Mazumdar-Shaw said it could take two-four years for them to hit the market."Well, I would love to develop a blockbuster drug with a `Made in India' label from our company", Shaw said.The company could well be on its way to achieving this dream - going by what Mazumdar-Shaw has to say. "We have a very interesting research pipeline. We are developing a number of products, which could be potential blockbusters," she added.She, however, had a word of caution about the research: "It is not something that can be predicted. Research is a very unpredictable business. If it happens, it's a huge bonanza. If it doesn't, it's a whole lot of money... You know..."She said the drugs being developed were in the areas of cancer and diabetes. "Most of these products will take at least two to four years before you can even think of accessing the markets."Mazumdar-Shaw, who was named among the world's 50 powerful women in business by Forbes last year, admits that stress is a part of life when one runs a business of Biocon's magnitude. Stock market expectations to keep performing and outperforming every quarter puts constant pressure on her."Right now, all of us get very stressed by business-related matters. There is constant pressure. Managing expectations is a challenge, and, of course, the demand on you to perform and outperform is very intense. Obviously, there is pressure in every quarter, but our business is something which cannot be judged on a quarterly basis. So, we are trying to educate the investor community to realise that they are not going to see exponential growth every quarter. It is a long-term business."She said intellectual wealth creation is about converting knowledge into wealth. "You use human capital, convert knowledge into wealth. You start with almost nothing and then you create the value. It is something to be proud of, and it shows that so much can be done in this country with education."She added that the biotech business was tough to run - no matter wherever one is in the world because it had inherent risks, long gestation periods and was a capital-intensive business. "Whether you are a man or woman, it is the same. It is tough for anyone."
